New Peer-Reviewed Study: Regular Ivermectin Use Led Up To 92% Reduction In Mortality From Covid-19

A box of the drug Ivermectine, made by Biogaran, is pictured on the counter of a pharmacy, as the spread of the coronavirus disease (COVID-19) continues, in Paris, France, April 28, 2020. (REUTERS/Benoit Tessier)

So is CNN still out there claiming that ivermectin is a ‘horse dewormer’ that should not be taken by Joe Rogan or anybody else who is attempting to kill the coronavirus? A new peer-reviewed study published Wednesday by the online medical journal Cureus found that periodic and repeated use of ivermectin led up to a 92% reduction in deaths from Covid-19.

This study was wide-scale, using a strictly controlled population of 88,012 participants, according to its authors.

Results for the effects of ivermectin were consequential. The study concluded, “Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and a seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin.” This, according to the authors, affirms the prophylactic effects of ivermectin against the Wuhan coronavirus. Participants outside of the control group were optionally prescribed a dose of 0.2 mg/kg/day of ivermectin for two consecutive days, every 15 days.

The results of this study come the same week the FDA granted an authorization of emergency which allows Pfizer to administer their new Covid-19 booster shot on children 12 years of age and older.

According to the FDA’s own words, they are continuing to grant these emergency authorizations because there are no adequate or available alternatives.

Per the FDA’s government website:

Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), when the Secretary of HHS declares that an emergency use authorization is appropriate, FDA may authorize unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN threat agents when certain criteria are met, including there are no adequate, approved, and available alternatives. The HHS declaration to support such use must be based on one of four types of determinations of threats or potential threats by the Secretary of HHS, Homeland Security, or Defense.

This statement appears to directly clash with postings by the NIH. A simple look at “COVID-19 Treatment Guidelines” section of their website shows a list of treatments titled “Antiviral Therapy.”

Such a list could suggest that there in fact may be “adequate,” “approved,” or “available” alternatives despite the FDA’s claims to the contrary.

Notably included on the list of antivirals is the drug Molnupiravir, a drug created by Merck, the same company that created ivermectin. Merck famously denounced usage of the now-generically priced drug in order to treat Covid-19, before later releasing Molnupiravir and touting it as a “COVID pill.” Big League Politics touched on the topic almost a year ago.

A full explanation of the procedures in the Cureus-published study can be found below:

Study procedures and data collection

Voluntary prophylactic use of ivermectin was offered as an option to patients during medical visits in a provisional outpatient clinic at the Convention Center and in secondary outpatient clinics at local health centers in the city of Itajaí, as part of the Universal Health System (SUS). During medical visits, patient data, including medical history, comorbidities, previous diseases, medications, and physical signs (body weight, height, body mass index, systolic and diastolic blood pressure, and heart rate), were recorded in the SUS-based system. ivermectin was then optionally prescribed in a dose of 0.2 mg/kg/day for two consecutive days, every 15 days to participants who presented without symptoms of COVID-19 or any contradictions to Ivermectin.

During the study, subjects who became infected with COVID-19 and diagnosed with a positive reverse transcription-polymerase chain reaction (RT-PCR) for SARS-CoV-2 were documented and medically followed up. Data on hospitalizations and deaths due to COVID-19 were also systematically registered.

In this analysis, all residents from the city of Itajaí were considered. This included participants in the program that used and did not use Ivermectin prophylactically. Registry data were analyzed for all participants included in the sample. Subjects with a positive diagnosis of COVID-19 before July 7, 2020, when the program was initiated, and those below 18 years old were excluded from the analysis.

The 223,128 residents from Itajaí included 114,568 participants aged 18 years and above, who used Ivermectin prophylactically and 45,716 who did not use Ivermectin, throughout the citywide program. Among these participants, 113,844 were not infected prior to July 7, 2020. This program also included 8,352 subjects aged 18 years and above from other cities that participated in the program, although not included in the present analysis.

While ivermectin non-users remained unchanged from the first analysis [25], ivermectin users were divided according to the accumulated dose of ivermectin taken.

The analysis focused on data for participants that used up to 60 mg (10 tablets) of ivermectin and those that used more than 180 mg (more than 30 tablets). Grouping the users in this manner represented a higher certainty of regularity and irregularity, respectively. These groups were compared to non-users in a three-group comparison analysis.

The three two-group matching of ivermectin, i.e., (1) non-users and regular users, (2) non-users and irregular users, and (3) regular users and irregular users, were balanced and matched using PSM with the following variables: age, sex, history of smoking, myocardial infarction (MI), stroke, hypertension, type 2 diabetes (T2D), cardiovascular diseases (CVD), cancer (any type), asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary diseases.

Because the accuracy of the reports was guaranteed for Itajaí residents only, all calculations and rates were based on the participants from the city. The database used for the calculation of COVID-19 infection rate and for risk of dying from COVID-19 was the entire city of Itajaí and then calculated among ivermectin regular users, irregular users, and non-users of participants from Itajaí. Analyses were performed before and after adjustment for multiple variables.

Hospitalization and mortality rates were analyzed for all participants reported with a positive COVID-19 diagnosis from Itajaí. Reports of all COVID-19 deaths were mandatory, while hospitalization rates were based on the data from the local public hospital only, which may justify potential discrepancies between hospitalization and mortality rates. We calculated hospitalization and hospitalization rates before matching and after PSM of groups, followed by a multivariate-adjusted analysis of the residual differences (double-adjusted model).

Support Big League Politics by making a donation today. You can also donate via PayPalVenmo or donate crypto. Your support helps us take on the powerful and report the truth that the mainstream media wants to silence.

Our Latest Articles